
Episode 4: Enavate Sciences’ Sara Nayeem
BioVenture VoiCes with Chris Garabedian
00:00
Duchenne and the ProSensa/Sarepta moment
Chris and Sara reflect on early Duchenne experiences, data volatility, and how those events influenced rare disease investing.
Play episode from 26:47
Transcript


